ProfileGDS5678 / 1425980_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 42% 41% 42% 42% 40% 51% 41% 41% 42% 45% 41% 41% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0960645
GSM967853U87-EV human glioblastoma xenograft - Control 22.9685242
GSM967854U87-EV human glioblastoma xenograft - Control 32.9531941
GSM967855U87-EV human glioblastoma xenograft - Control 42.922542
GSM967856U87-EV human glioblastoma xenograft - Control 52.9243142
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0139540
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3149851
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9427841
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9147341
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9554742
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0376445
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9046641
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9494441
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9558142